NR1H3 and Other metabolic disease: Nuclear receptor LXR (lxralpha, NR1H3) is another transcriptional regulator of GLUT5 expression identified in mice and human that is thought to be a potential pharmaceutical target for selective modulation of GLUT5 expression in context to cancer and metabolic disease [46].